The drug, which was used in 4% of breast cancer clinical trials conducted in 2018, was investigated for its use as a combination therapy in the vast majority of cases.
As the Brexit crisis continues to spiral, new findings from GlobalData reveal that 83% of healthcare professionals in the UK believe that the country will no longer present an attractive destination